Get started
GILEAD SCIENCES DL-,001GILEAD SCIENCES DL-,001GILEAD SCIENCES DL-,001

GILEAD SCIENCES DL-,001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

GIS trade ideas

$GILD Time to be BULLISH on Gilead Sciences.Gilead reported earnings on Thursday and it may be finally turning the corner. GILD was considered a one trick pony due to the success of its Hepatitis drugs, which unfortunately have starting to drop in revenue. That decline has been meet with a rising revenue stream from new HIV treatments, which tend to be longer term treatments than Hepatitis cases. As a result of recent acquisitions, Oncology is also a growing revenue stream with Yescarta more than doubling revenue to $96m in the first quarter. GILEAD also has a sizable cash at hand of $30 Billion along with a very strong balance sheet. Analysts have a overweight rating on the stock and a average price target of $81, we expect some upgrades in the days to come. NASDAQ:GILD Company Description Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.
NASDAQ:GILDLong
by RedHotStocks
GILD for a Long PlayShares of GILD have recently broken out above resistance around $74 and have since successfully tested and held it as support (dashed green line) on two different occasions. They look destined to at least test the falling trend line (red line), and I think there's a good chance we break through that resistance to establish a new trend higher. I'm a buyer via calls, specifically the November $80 calls because they will carry me through the next earnings report. That's not to say I'll hold them through the release, but I suspect premiums will elevate leading in to the report and that should help bolster the bullish position.
NASDAQ:GILDLong
by EchoAlphaBravo